Jared Martin
Family · Palmer, AKNPI 1659860724
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.4% of the total across 70 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 18.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $610 and has fallen 57.4% since, to $260 in 2025.
Across 70 payments — averaging $25.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$327
- AbbVie$242
- Neurocrine Biosciences, Inc.$216
- Abbott$173
- Otsuka America Pharmaceutical, Inc.$124
- Amgen$111
- plus $608 from 17 others
What the payments were for
- Food & beverage$1,75497%
- Education$473%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 13 | $327 |
| AbbVie | 8 | $242 |
| Neurocrine Biosciences, Inc. | 5 | $216 |
| Abbott | 1 | $173 |
| Otsuka America Pharmaceutical, Inc. | 7 | $124 |
| Amgen | 4 | $111 |
| Novartis | 4 | $87 |
| Alkermes, Inc. | 3 | $85 |
| AstraZeneca | 4 | $76 |
| Vanda Pharmaceuticals Inc. | 4 | $55 |
| Lilly USA, LLC | 2 | $47 |
| Tersera Therapeutics LLC | 1 | $32 |
| Johnson & Johnson | 2 | $31 |
| Lundbeck LLC | 2 | $27 |
| Teva Pharmaceuticals USA, Inc. | 2 | $23 |
| Exact Sciences | 1 | $23 |
| Pfizer | 1 | $22 |
| Mylan Specialty L.p. | 1 | $21 |
| Eisai Inc. | 1 | $20 |
| Nevro Corp. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
| Ironshore Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,801 in reported general payments places this provider in the 85th percentile of 315 family providers in Alaska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rosuvastatin Calcium | 26 | $592 |
| Levothyroxine Sodium | 13 | $129 |
| Metformin Hcl ErMetformin Hcl | 14 | $118 |
| Ezetimibe | 14 | $104 |
Paid to pharmacies, not to this prescriber.
Other family in Palmer
- Melinda NoblePalmer$5K
- Kristen AlcornPalmer$3K
- Darrel FoisterPalmer$1K
- Erica HeagyAnchorage$249K
- Trisha KernodleAnchorage$60K
- Whitney CarlsonSoldotna$16K
- Randi HallSoldotna$16K
- Kristy BloodFairbanks$7K
- Casey BloodFairbanks$7K
- Marisha DietersAnchorage$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.